- Home
- YRD vs ORKA Comparison
YRD vs ORKA Comparison
Compare YRD & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YRD
- ORKA
- Stock Information
- Founded
- YRD 2012
- ORKA 2004
- Country
- YRD China
- ORKA United States
- Employees
- YRD N/A
- ORKA N/A
- Industry
- YRD Finance: Consumer Services
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- YRD Finance
- ORKA Health Care
- Exchange
- YRD Nasdaq
- ORKA Nasdaq
- Market Cap
- YRD 495.5M
- ORKA 429.4M
- IPO Year
- YRD 2015
- ORKA N/A
- Fundamental
- Price
- YRD $5.70
- ORKA $9.22
- Analyst Decision
- YRD
- ORKA Strong Buy
- Analyst Count
- YRD 0
- ORKA 7
- Target Price
- YRD N/A
- ORKA $39.67
- AVG Volume (30 Days)
- YRD 196.4K
- ORKA 382.5K
- Earning Date
- YRD 03-20-2025
- ORKA 05-15-2025
- Dividend Yield
- YRD 6.76%
- ORKA N/A
- EPS Growth
- YRD N/A
- ORKA N/A
- EPS
- YRD 2.48
- ORKA N/A
- Revenue
- YRD $795,426,969.00
- ORKA N/A
- Revenue This Year
- YRD N/A
- ORKA N/A
- Revenue Next Year
- YRD N/A
- ORKA N/A
- P/E Ratio
- YRD $2.30
- ORKA N/A
- Revenue Growth
- YRD 18.59
- ORKA N/A
- 52 Week Low
- YRD $4.12
- ORKA $5.49
- 52 Week High
- YRD $9.20
- ORKA $53.88
- Technical
- Relative Strength Index (RSI)
- YRD 41.70
- ORKA N/A
- Support Level
- YRD $5.56
- ORKA N/A
- Resistance Level
- YRD $5.95
- ORKA N/A
- Average True Range (ATR)
- YRD 0.45
- ORKA 0.00
- MACD
- YRD -0.08
- ORKA 0.00
- Stochastic Oscillator
- YRD 36.50
- ORKA 0.00
About YRD Yiren Digital Ltd.
Yiren Digital Ltd is an advanced, AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.